DISCLAIMER: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

August 14, 2026

To whom it may concern,

Company name:	Heartseed Inc.
Representative:	Keiichi Fukuda, MD/PhD/FACC, CEO, Representative Director of the Board
Securities code:	219A, Tokyo Stock Exchange
Inquiries:	Akira Masuda, Head of Strategic Finance and IR Department TEL: +81-(0)3-6665-8068 (IR)

Notice Concerning the Conclusion of a Special Overdraft Agreement

Heartseed Inc. (the "Company") hereby announces that its Board of Directors, at a meeting held on August 14, 2026, resolved to execute a special overdraft agreement (the "Agreement") as described below.

1. Purpose of this Agreement

The Company is advancing research and development, as well as business development, of "cardiomyocyte replacement therapy," which involves the direct transplantation of allogeneic iPS cell-derived cardiomyocyte spheroids into the heart of patients with severe heart failure. At present, regarding our lead pipeline, the therapeutic program using open-chest administration of allogeneic iPS cell-derived cardiomyocyte spheroids (HS-001), we have completed the analysis in the Phase I/II clinical trial (LAPiS study) and obtained results supporting the Company's plan toward applying for manufacturing and marketing approval. We are currently proceeding with discussions with the Pharmaceuticals and Medical Devices Agency (PMDA), aiming to submit the application for manufacturing and marketing approval within 2026.

The purpose of this Agreement is to secure a credit facility for the funds necessary for activities toward the application for manufacturing and marketing approval of HS-001, as well as the prompt establishment of a manufacturing and sales structure, etc. after approval. Through this, we will increase liquidity on hand and promote our business activities more flexibly and steadily.

2. Overview of the Agreement

Lender	Sumitomo Mitsui Banking Corporation
Credit limit	2 billion yen
Contract date	August 14, 2026
Contract period	1 year
Contract interest rate	Floating interest rate
Collateral and guarantees	Unsecured and un-guaranteed

3. Future Outlook

There is no revision to the latest earnings forecast for the fiscal year ending December 31, 2026.

(Cautionary notice on forward-looking information)

The financial results forecasts and other forward-looking information contained in this document are based on the information currently available to the Company and certain assumptions considered reasonable by the Company. It is not a guarantee that the forecasts will be achieved, and actual results may differ significantly from such forecasts depending on various factors.